Retatrutide 60MG

Retatrutide is a next‑generation triple‑agonist peptide that simultaneously activates the GLP‑1, GIP, and glucagon receptors, making it one of the most potent multi‑pathway metabolic research compounds available. In controlled laboratory environments, this receptor combination is studied for its ability to influence energy expenditure, glucose regulation, lipid metabolism, and adiposity signaling.

GLP‑1 Activation

Supports insulin secretion, slows gastric emptying, and modulates glucose control pathways.

GIP Activation

Enhances insulin response and is studied for its role in lipid processing and metabolic efficiency.

Glucagon Activation

Increases energy expenditure, promotes fat oxidation, and influences hepatic glucose output.